Introduction: Expedited partner therapy (EPT) may reduce Chlamydia trachomatis reinfection. This pilot study was conducted to determine if female adolescents with C. trachomatis accept and deliver EPT to male sexual partners and whether it is associated with decreased C. trachomatis reinfection rates at 3 and 6 months.
Method: Forty-six female adolescents, aged 13 to 19years and diagnosed with C. trachomatis at two urban school-based health centers, participated in four visits over 6 months. Participants completed a self-administered self-efficacy scale and a sexual risk behavior and EPT questionnaire and were retested for C. trachomatis 3 and 6 months after treatment.
Results: Overall, 65% accepted EPT, and 73% of those who accepted EPT delivered EPT to their partners. Eighty percent completed the 3-month visit, of these, 30% tested positive for C. trachomatis; 57% completed the 6-month visit, and of these, 15% tested positive for C. trachomatis. Acceptance of EPT was associated with reductions in C.trachomatis reinfection at 3 months (p = .04) but not at 6 months (p = .10). Delivery of EPT was not associated with reductions in C. trachomatis reinfection at 3 or 6 months (p = .08 and p = .44, respectively). Self-efficacy scales did not predict acceptance and delivery of EPT.
Discussion: Although two-thirds of participants accepted EPT and acceptance of EPT was associated with reductions in C. trachomatis reinfection at 3 months, rates of reinfection were high. Implications of these findings are limited by the small sample size. Larger studies are needed to understand potential barriers to delivery of EPT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pedhc.2018.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of a community-based intervention for sexually transmitted infections on population-level prevalence among youth in Zimbabwe (STICH): a cluster-randomised trial.
Lancet Glob Health
January 2025
Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK; The Health Research Unit Zimbabwe, Biomedical Research and Training Institute, Harare, Zimbabwe.
Background: Young people are at particularly high risk of acquiring sexually transmitted infections (STIs). We conducted a trial to investigate the effect of a community-based intervention that included STI screening among youth on population-level prevalence of STIs in Zimbabwe.
Methods: STICH was a parallel-arm, cluster-randomised controlled trial nested within CHIEDZA, a trial of community-based integrated HIV and sexual and reproductive health services for youth in Zimbabwe.
Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease.
PLoS Negl Trop Dis
August 2024
Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Article Synopsis
- - Trachoma is a major cause of infection-related blindness, resulting from repeated infections by Chlamydia trachomatis, which lead to two phases: acute inflammation and long-term scarring due to the severity of reinfections.
- - Researchers conducted a study using Cynomolgus monkeys to observe the immune response to acute conjunctival infections of Ct, finding similar clinical signs to those in humans and detailed immune kinetics over several weeks.
- - The study concluded that this monkey model effectively replicates acute trachoma symptoms, facilitating a deeper understanding of immune responses that could aid in developing a vaccine against the disease.
Objective: The aim of the study is to evaluate adherence to national recommendations for Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) testing during pregnancy including tests for cure/clearance and for persistence/potential reinfection at time of delivery.
Materials And Method: We evaluated results of chlamydia and gonorrhea nucleic acid amplification tests (NAAT) performed by major national reference laboratory from January 2010 through July 2022.
Results: Of 3,519,781 uniquely identified pregnant individuals, we identified 4,077,212 pregnancies.
Effective Treatment of Lymphogranuloma Venereum With a 7-Day Course of Doxycycline.
Sex Transm Dis
July 2024
Department of Sexual Health/HIV Medicine, Western Health & Social Care Trust, Derry, Northern Ireland, United Kingdom.
Article Synopsis
- Lymphogranuloma venereum (LGV) is prevalent in the UK, mainly affecting gay, bisexual, or other men who have sex with men (GBMSM), and recent studies indicate that a shorter 7-day doxycycline treatment may be as effective as the standard 21-day course.
- The study involved reviewing cases from a South London sexual health service where 52 GBMSM, including some with HIV and other STIs, were treated with 7 days of doxycycline; most individuals were asymptomatic and follow-up showed successful eradication of LGV.
- The findings suggest that a 7-day doxycycline treatment could be routinely recommended for those with mild symptoms or
Interferon-γ Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Women With Different Chlamydia Outcomes.
J Infect Dis
September 2024
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Background: Chlamydia trachomatis testing and treatment strategies have not decreased infection rates, justifying need for a chlamydia vaccine. A murine study showed that a vaccine consisting of major outer membrane protein (MOMP) and polymorphic membrane proteins (Pmps) E, F, G, and H elicited protective immunity; studies on human cellular immune responses to Pmps are sparse.
Methods: Interferon gamma (IFN-γ) responses to these 5 proteins were measured by ELISPOT in peripheral blood mononuclear cells from women returning for treatment of a positive chlamydia test.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!